Loading
Shame electropuncture / Post Stroke Depression / Dexmedetomidine · Phase 4 Trial
ClinicalTrials.gov · July 31, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a planned Phase 4 trial of combined electroacupuncture and dexmedetomidine for prevention of post-stroke depression, currently in pre-recruitment status. No outcome data are available from this registry record; the study aims to evaluate incidence of post-stroke depression at 3 months post-stroke. Readers should await publication of results before drawing clinical conclusions.
Phase 4, Interventional, Randomized, Parallel, Double masking, Prevention purpose. Post-stroke Depression. Intervention: Electroacupuncture group; The electroacupuncture combined with dexmedetomidine group. Compared with: Control group — Placebo Comparator. n = 231.
This is a planned Phase 4 trial of combined electroacupuncture and dexmedetomidine for prevention of post-stroke depression, currently in pre-recruitment status. No outcome data are available from this registry record; the study aims to evaluate incidence of post-stroke depression at 3 months post-stroke. Readers should await publication of results before drawing clinical conclusions.
Effect sizes, comparisons between arms, safety data, and secondary outcomes are not reported.
The source did not state who this applies to in practice.
This is a clinical trial registration with no reported results; the study is not yet recruiting and outcome data are unavailable.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07739329). This is a study registration, not published results. Lead sponsor: Min Su. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE4. Study type: INTERVENTIONAL. Enrollment: 231 participants (ESTIMATED). Conditions: Post-stroke Depression. Interventions: DRUG: Dexmedetomidine; DRUG: Electropuncture; DRUG: Normal Saline (NS); DRUG: Shame electropuncture. Primary outcome measures: The incidence of PSD 3 months after stroke , 3 months after stroke. Brief summary: Post-stroke depression (PSD) is a common neuropsychiatric complication following stroke and has emerged as a major public health concern due to its adverse impact on post-stroke prognosis. Clinical studies have confirmed that early intervention with electroacupuncture can significantly reduce PSD incidence and alleviate depressive severity. Mechanistically, electroacupuncture exerts antidepressant effects through inhibition of the endoplasmic reticulum stress pathway and attenuation of neuronal apoptosis. Dexmedetomidine, a highly selective α₂-adrenergic receptor agonist, not only provides sedation and analgesia but also confers neuroprotective actions, including anti-inflammatory, anti-apoptotic, and blood-brain barrier protective effects. Its efficacy in preventing postpartum depression has been clinically validated. Given the substantial burden of PSD and the limitations of existing preventive approaches, the present study aims to investigate the value of a combined electroacupuncture and dexmedetomidine strategy for PSD prevention, with the goal of developing a safe and effective integrative treatment regimen for this frequent post-stroke complication.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.